Bristol Myers Squibb (BMY) Stock Forecast & Price Target

$54.34 -0.61 (-1.10%)

Closing price 03:59 PM Eastern

Extended Trading

$54.37 +0.02 (+0.04%)

As of 06:30 PM Eastern

Compare

Bristol Myers Squibb - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 19 Analyst Ratings

Sell
1

Hold
10

Buy
8

Based on 19 Wall Street analysts who have issued ratings for Bristol Myers Squibb in the last 12 months, the stock has a consensus rating of "Hold." Out of the 19 analysts, 1 has given a sell rating, 10 have given a hold rating, and 8 have given a buy rating for BMY.

Consensus Price Target

$61.31
12.83% Upside

According to the 19 analysts' twelve-month price targets for Bristol Myers Squibb, the average price target is $61.31. The highest price target for BMY is $75.00, while the lowest price target for BMY is $40.00. The average price target represents a forecasted upside of 12.83% from the current price of $54.34.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for BMY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Bristol Myers Squibb and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BMY Analyst Ratings Over Time

Type	Current Forecast 6/2/25 to 6/2/26	1 Month Ago 5/3/25 to 5/3/26	3 Months Ago 3/4/25 to 3/4/26	1 Year Ago 6/2/24 to 6/2/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	9 Buy rating(s)	3 Buy rating(s)
Hold	10 Hold rating(s)	10 Hold rating(s)	12 Hold rating(s)	13 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$61.31	$61.31	$60.71	$58.00
Forecasted Upside	12.83% Upside	5.27% Upside	-2.59% Downside	18.95% Upside
Consensus Rating	Hold	Hold	Hold	Hold

BMY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BMY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Bristol Myers Squibb Stock vs. The Competition

Type	Bristol Myers Squibb	Medical Companies	Broader Market
Consensus Rating Score	2.37	2.30	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	12.83% Upside	1,731.01% Upside	15.35% Upside
News Sentiment Rating	Positive News See Recent BMY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
5/28/2026	UBS Group 4 of 5 stars		Reiterated Rating	Buy
5/1/2026	Citigroup 4 of 5 stars		Reiterated Rating	Neutral
4/9/2026	Bank of America 4 of 5 stars	Tim Anderson Not Rated	Lower Target	Buy	$68.00 ➝ $67.00	+12.93%
4/8/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Carter Gould Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$45.00 ➝ $54.00	-6.38%
4/8/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Seamus Fernandez Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$72.00	+24.82%
3/23/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold (C)
3/17/2026	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rajesh Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$53.00 ➝ $60.00	-0.91%
2/24/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Trung Huynh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Sector Perform	$60.00	-2.62%
2/23/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Amsellem Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$66.00 ➝ $75.00	+23.65%
2/19/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Emily Field Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Underweight ➝ Overweight	$75.00	+24.33%
Stranded On The Flood Plains of History (Ad) The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar. Read Porter's full briefing and get the ticker names today
2/6/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terence Flynn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Underweight	$40.00	-34.88%
2/6/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$55.00 ➝ $60.00	+0.95%
1/13/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Risinger Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$54.00 ➝ $60.00	+6.39%
1/9/2026	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Louise Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Sector Perform	$53.00 ➝ $60.00	+7.82%
12/3/2025	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Srikripa Devarakonda Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$65.00	+27.53%
12/2/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Asad Haider Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral	$51.00 ➝ $57.00	+15.99%
11/17/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Market Perform
11/3/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Market Perform
10/2/2025	Dbs Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Moderate Buy
8/5/2025	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Narumi Nakagiri Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$42.00	-7.47%
4/25/2025	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jasper Hellweg Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold
4/25/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Market Perform
4/23/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Akash Tewari Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$70.00 ➝ $68.00	+36.49%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alexandria Hammond Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Peer Perform
10/7/2024	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Hold	$53.00 ➝ $59.00	+9.32%
7/23/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Hold	$53.00 ➝ $45.00	+5.36%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 06:20 PM ET.

Should I Buy Bristol Myers Squibb Stock? BMY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, May 29, 2026. Please send any questions or comments about these Bristol Myers Squibb pros and cons to contact@marketbeat.com.

Bristol Myers Squibb
Bull Case

Here are some ways that investors could benefit from investing in Bristol-Myers Squibb:

The company is set to unveil new data at ASCO 2026, which may highlight the strength of its oncology portfolio and next-generation pipeline, potentially boosting investor confidence in future growth.
Bristol-Myers Squibb has a diverse product lineup, including recent advancements in treatments for various cancers and other serious diseases, which positions it well in the biopharmaceutical market.
The current stock price is around $61.31, reflecting a consensus target price that suggests potential for growth based on analysts' ratings.
Several analysts have recently upgraded their target prices for the stock, indicating positive sentiment and expectations for the company's performance.
The company has a strong focus on research and development, which is crucial for long-term growth in the competitive biopharmaceutical industry.

Bristol Myers Squibb
Bear Case

Investors should be bearish about investing in Bristol-Myers Squibb for these reasons:

There are ongoing concerns regarding patent expirations, which could impact the company's revenue from key products and create uncertainty for investors.
Market commentary suggests a cautious balance between the potential of the pipeline and the risks associated with upcoming data readouts, which may affect stock performance.
Some analysts have issued "underweight" ratings, indicating that they believe the stock may not perform as well as the market or its peers.
The competitive landscape in the biopharmaceutical sector is intense, with many companies vying for market share, which could pressure Bristol-Myers Squibb's growth.
Investors may face volatility in stock performance due to market reactions to clinical trial results and regulatory approvals, which can be unpredictable.

BMY Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Bristol Myers Squibb is $61.31, with a high forecast of $75.00 and a low forecast of $40.00.

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bristol Myers Squibb in the last year. There is currently 1 sell rating, 10 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BMY, but not buy additional shares or sell existing shares.

According to analysts, Bristol Myers Squibb's stock has a predicted upside of 12.83% based on their 12-month stock forecasts.

Bristol Myers Squibb has been rated by research analysts at Bank of America, Cantor Fitzgerald, Citigroup, Guggenheim, HSBC, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like Bristol Myers Squibb more than other "medical" companies. The consensus rating score for Bristol Myers Squibb is 2.37 while the average consensus rating score for "medical" companies is 2.30. Learn more on how BMY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Bristol Myers Squibb Recommendations

This page (NYSE:BMY) was last updated on 6/2/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bristol Myers Squibb (BMY) Stock Forecast & Price Target

Bristol Myers Squibb - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

BMY Analyst Ratings Over Time

BMY Analyst Recommendations By Month

BMY Price Targets by Month

Bristol Myers Squibb Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Bristol Myers Squibb Stock? BMY Pros and Cons Explained

Bristol Myers Squibb
Bull Case

Bristol Myers Squibb
Bear Case

BMY Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Bristol Myers Squibb Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bristol Myers Squibb (BMY) Stock Forecast & Price Target

Bristol Myers Squibb - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

BMY Analyst Ratings Over Time

BMY Analyst Recommendations By Month

BMY Price Targets by Month

Bristol Myers Squibb Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Bristol Myers Squibb Stock? BMY Pros and Cons Explained

Bristol Myers Squibb Bull Case

Bristol Myers Squibb Bear Case

BMY Forecast - Frequently Asked Questions

What is Bristol Myers Squibb's forecast for 2026?

Should I buy or sell Bristol Myers Squibb stock right now?

Does Bristol Myers Squibb's stock price have much upside?

What analysts cover Bristol Myers Squibb?

Do Wall Street analysts like Bristol Myers Squibb more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Bristol Myers Squibb Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Bristol Myers Squibb
Bull Case

Bristol Myers Squibb
Bear Case